TNF and temporal arteritis: A number of case reports have also described benefits of infliximab and adalimumab in the treatment of CS-resistant GCA [41–43]; however, three randomized, double-blind, placebo-controlled trials of TNF-α inhibition failed to demonstrate a benefit [44–46].